Vesicular stomatitis virus (VSV), an enveloped, negative-strand RNA virus, belongs to the Vesiculovirus genus of the Rhabdoviridae family. VSV has the ability to infect and kill cancer cells while sparing normal cells. VSV is a rapidly replicating, potently immunogenic virus which is amenable to engineering and has been deployed as a platform to develop prophylactic and therapeutic vaccines to prevent and/or treat infectious disease and oncolytic viruses for the treatment of cancer. Recombinant attenuated VSV vectors have been shown to replicate selectively in and kill cancer cells and are not pathogenic in humans. Tumor selectivity is due largely to cancer-specific defects in innate immune response pathways preventing malignant cells from mounting an effective antiviral response rendering them permissive to virus replication and killing. VSV is a particularly promising vector for development as an oncolytic therapy due to the lack of preexisting immunity to VSV in the general human population, allowing the development of agents that can potentially be administered systemically for the treatment of disseminated and metastatic cancers.
Figure 1. Scheme of VSV-based OV therapy.
Creative Biogene has developed an all-sided QVirus™ platform, with this advanced platform, we offer customized, standardized and high-quality oncolytic vesicular stomatitis virus services for clients globally. By virtue of QVirus™, we are able to design, engineering and generate the most efficacious oncolytic vesicular stomatitis viral products.
Recombinant VSV in which native envelope G protein is replaced with a foreign reporter gene such as a fluorescent reporter protein, luciferase, or secreted alkaline phosphatase (SEAP) can normally bud from producing cells even in the absence of G protein, and heterologous viral envelope proteins are incorporated into the virion. We also provide recombinant VSV production services based on customer demand.
We have established comprehensive VSV reverse genetics systems and many advances have been done to precisely edit the viral genome. Reverse genetics (the methods established to recover infectious recombinant virus from cDNA) enables the use of genetic engineering of VSV to study all aspects of the virus life cycle and to create rVSVs better suited for vaccine and oncolytic applications.
A pseudotype virus is defined as a viral particle harboring other types of viral envelopes or host cellular proteins with or without its own envelope. By virtue of these characteristics of VSV, pseudotype virus systems, in which VSV G proteins are completely replaced with other types of viral envelope proteins, have been established. Numerous types of pseudotype viruses have been constructed at QVirus™ platform with heterologous viral envelope proteins and used in studies examining the entry of viruses, for identification of novel viral receptors, for development of neutralization tests, and as vaccine vectors.
QVirus™ platform has the ability to modify your VSV product based on your need. With our platform, we could provide one-stop service for your virus-related project. The proof-of-concept validation study for the oncolytic virus was provided by our platform as well. If you have any special requirements, please feel free to contact us.
1. Tani H, et al. Development and applications of VSV vectors based on cell tropism. Frontiers in Microbiology, 2012, 2: 272.
2. Velazquez-Salinas L, et al. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) is nonpathogenic and nontransmissible in pigs, a natural host of VSV. Human Gene Therapy Clinical Development, 2017, 28(2): 108-115.
3. Hastie E, Grdzelishvili V Z. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. The Journal of general virology, 2012, 93(Pt 12): 2529.